413 related articles for article (PubMed ID: 25267595)
21. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA; Taddei T; Jain D; Zhang X
Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
[TBL] [Abstract][Full Text] [Related]
22. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
23. Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma.
Luang S; Teeravirote K; Saentaweesuk W; Ma-In P; Silsirivanit A
Medicina (Kaunas); 2020 Nov; 56(11):. PubMed ID: 33207685
[No Abstract] [Full Text] [Related]
24. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D; Villanueva A; Friedman SL; Llovet JM
Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
[TBL] [Abstract][Full Text] [Related]
25. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Wiggers JK; Ruys AT; Groot Koerkamp B; Beuers U; ten Kate FJ; van Gulik TM
J Gastroenterol Hepatol; 2014 Aug; 29(8):1582-94. PubMed ID: 24787096
[TBL] [Abstract][Full Text] [Related]
26. Cholangiocarcinoma.
Razumilava N; Gores GJ
Lancet; 2014 Jun; 383(9935):2168-79. PubMed ID: 24581682
[TBL] [Abstract][Full Text] [Related]
27. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract][Full Text] [Related]
28. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
29. Survival and Causes of Death among Patients with Intrahepatic Cholangiocarcinoma in the United States from 2000 to 2018.
Elgenidy A; Afifi AM; Jalal PK
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2169-2176. PubMed ID: 36099432
[TBL] [Abstract][Full Text] [Related]
30. Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis.
Takahashi K; Obeid J; Burmeister CS; Bruno DA; Kazimi MM; Yoshida A; Abouljoud MS; Schnickel GT
Ann Transplant; 2016 Apr; 21():208-15. PubMed ID: 27068242
[TBL] [Abstract][Full Text] [Related]
31. Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma".
Braxton DR; Saxe D; Damjanov N; Stashek K; Shroff S; Morrissette JD; Tondon R; Furth EE
Hum Pathol; 2017 Apr; 62():232-241. PubMed ID: 28232156
[TBL] [Abstract][Full Text] [Related]
32. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
[TBL] [Abstract][Full Text] [Related]
33. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
34. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
35. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
36. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
37. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases.
Wang Q; Xu Y; Wang SM; Hu AY; Pan YC; Zhang SH
Ann Diagn Pathol; 2021 Dec; 55():151828. PubMed ID: 34571341
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
Tang Z; Yang Y; Zhang Q; Liang T
Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
[TBL] [Abstract][Full Text] [Related]
40. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
